Merus N.V.

MRUS

$94.38

Name : Merus N.V.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $7,152,535,040.00

EPSttm : -5.58

Merus N.V.

$94.38

0.01%

$0.01

Float Short %

6.36

Margin Of Safety %

Put/Call OI Ratio

0.98

EPS Next Q Diff

1.03

EPS Last/This Y

-2.25

EPS This/Next Y

1.04

Price

94.36

Target Price

Analyst Recom

2.76

Performance Q

71.26

Relative Volume

2.09

Beta

1.27

Ticker: MRUS

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-09	MRUS	68.55	0.64	0.89	25859
2025-09-10	MRUS	67.13	0.66	0.03	28018
2025-09-11	MRUS	69.82	0.67	1.61	30266
2025-09-12	MRUS	69.26	0.65	0.08	28231
2025-09-15	MRUS	67.9	0.65	0.21	28234
2025-09-16	MRUS	66.87	0.64	0.17	28224
2025-09-17	MRUS	68.18	0.66586566639315	0.083333333333333	28423
2025-09-18	MRUS	68.93	0.67	0.04	28431
2025-09-19	MRUS	67.9	0.67	0.06	28372
2025-09-22	MRUS	69.23	0.51	0.05	19860
2025-09-23	MRUS	68.14	0.50	1.12	20067
2025-09-24	MRUS	68.57	0.51	1.06	20249
2025-09-25	MRUS	67.78	0.52	0.04	20390
2025-09-26	MRUS	68.86	0.52	0.10	20405
2025-09-29	MRUS	93.58	0.52	1.06	20405
2025-09-30	MRUS	94.14	0.91	0.48	40083
2025-10-01	MRUS	94.11	0.90	0.31	42422
2025-10-02	MRUS	94.18	0.88	5.23	43083
2025-10-03	MRUS	94.19	0.98	1.22	46624
2025-10-06	MRUS	94.29	0.98	3.28	46530
2025-10-07	MRUS	94.37	0.98	0.60	46651
2025-10-08	MRUS	94.36	0.98	7.00	47014
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-09	MRUS	68.60	9.7	-28.2	-5.79
2025-09-10	MRUS	67.14	9.7	-10.5	-5.79
2025-09-11	MRUS	69.80	9.7	-36.3	-5.79
2025-09-12	MRUS	69.62	9.7	-18.2	-5.79
2025-09-15	MRUS	68.09	9.7	-9.9	-5.79
2025-09-16	MRUS	66.90	9.7	-11.8	-5.79
2025-09-17	MRUS	68.21	9.7	-27.6	-5.79
2025-09-18	MRUS	68.92	9.7	-23.8	-5.79
2025-09-19	MRUS	68.25	10.1	-14.9	-5.72
2025-09-22	MRUS	69.19	10.1	-25.2	-5.72
2025-09-23	MRUS	68.22	10.1	-13.3	-5.72
2025-09-24	MRUS	68.25	10.1	-19.4	-5.72
2025-09-25	MRUS	68.10	10.1	-18.4	-5.72
2025-09-26	MRUS	68.89	10.1	-24.2	-5.72
2025-09-29	MRUS	93.66	10.1	-172.6	-5.72
2025-09-30	MRUS	94.13	6.6	-21.3	-5.72
2025-10-01	MRUS	94.13	6.6	-19.2	-5.59
2025-10-02	MRUS	94.17	6.5	-19.4	-5.60
2025-10-03	MRUS	94.25	6.5	-19.7	-5.60
2025-10-06	MRUS	94.29	6.5	-19.8	-5.60
2025-10-07	MRUS	94.37	6.5	-19.7	-5.60
2025-10-08	MRUS	94.36	6.5	-19.1	-5.60
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-09	MRUS	-1.12	6.40	6.53
2025-09-10	MRUS	-1.12	6.40	6.53
2025-09-11	MRUS	-1.12	6.40	6.41
2025-09-12	MRUS	-1.12	6.40	6.41
2025-09-15	MRUS	-1.12	6.41	6.41
2025-09-16	MRUS	-1.12	6.41	6.41
2025-09-17	MRUS	-1.12	6.41	6.41
2025-09-18	MRUS	-1.12	6.41	6.41
2025-09-19	MRUS	-1.12	6.41	6.41
2025-09-22	MRUS	-1.12	6.40	6.41
2025-09-23	MRUS	-1.12	6.40	6.41
2025-09-24	MRUS	-1.12	6.40	6.41
2025-09-25	MRUS	-1.12	6.40	6.37
2025-09-26	MRUS	-1.07	6.40	6.37
2025-09-29	MRUS	-1.07	6.37	6.37
2025-09-30	MRUS	-1.07	6.37	6.37
2025-10-01	MRUS	-1.07	6.37	6.37
2025-10-02	MRUS	-1.07	6.37	6.37
2025-10-03	MRUS	-1.07	6.37	6.36
2025-10-06	MRUS	-1.07	4.47	6.36
2025-10-07	MRUS	-1.07	4.47	6.36
2025-10-08	MRUS	-1.07	4.47	6.36
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-2.23

Avg. EPS Est. Current Quarter

-1.36

Avg. EPS Est. Next Quarter

-1.2

Insider Transactions

-1.07

Institutional Transactions

4.47

Beta

1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

0.2

Max Drawdown 5-Year %

-60.4

Target Price

P/E

Forward P/E

PEG

P/S

127.2

P/B

8.47

P/Free Cash Flow

EPS

-5.54

Average EPS Est. Cur. Y

-5.6

EPS Next Y. (Est.)

-4.57

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-685.64

Relative Volume

2.09

Return on Equity vs Sector %

-71

Return on Equity vs Industry %

-57.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.19

EBIT Estimation

-19.1

Merus N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 260

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

stock quote shares MRUS – Merus N.V Stock Price stock today

news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch MRUS – Merus N.V yahoo finance google finance

stock history MRUS – Merus N.V invest stock market

stock prices MRUS premarket after hours

ticker MRUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y